Infect. Immun. 64:2709-2715, 1996). The safety and immunogenicity of the two conjugates were then evaluated sequentially in Vietnamese adults, teenagers, and 2-to 4-year-old children. None of the vaccinees experienced significant side effects, and all had preexisting LPS antibodies. At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >80% of the volunteers. SPA-TT 2 elicited slightly higher, though not statistically significantly, levels of IgG anti-LPS than did SPA-TT 1 in these age groups. Accordingly, only SPA-TT 2 was evaluated in the 2-to 4-year-old children. On a random basis, one or two injections were administered 6 weeks apart to the children. No significant side effects were observed, and the levels of preexisting anti-LPS in serum were similar in children of all ages. A significant rise in the IgG anti-LPS titer was elicited by the first injection (P ‫؍‬ 0.0001); a second injection did not elicit a booster response. Representative sera from all groups had bactericidal activity that could be adsorbed by S. enterica serovar Paratyphi A LPS.
Enteric fever, with its septicemia and complications, is caused by Salmonella serogroups A, B, C, and D. Although reported throughout the world several decades ago (2, 13) , Salmonella enterica serovar Paratyphi A seems to be confined to Southeast Asia, where it is the second most common cause of enteric fever, accounting for about 10% of cases (1, 3, 19, 22, 25, 28, 29, 31, 36, 37, 39-43, 46-48, 55, 57, 62, 63, 66) . Despite the frequency and severity of enteric fevers and efforts to control the diseases, there is no licensed vaccine for nontyphoidal salmonellae. TAB vaccine, composed of inactivated Salmonella, was removed as a licensed product because efficacy could not be verified for groups A and B (17, 20, 26, 59) .
Both S. enterica serovars Typhi and Paratyphi are inhabitants and pathogens of humans only, and they can be considered clones (11, 21, 24, 32, 45, 49, 53, 58) . The lipopolysaccharide (LPS) of nontyphoidal Salmonella is both an essential virulence factor and a protective antigen (50) . Animal experiments on the structurally related serogroup B and clinical results with Vi capsular polysaccharide of S. enterica serovar Typhi were the basis for our prediction that a critical level of serum immunoglobulin G (IgG) to the O-specific polysaccharide (O-SP) will confer protection against S. enterica serovar Paratyphi A (10, 15, 16, 50, 58, 64) . Accordingly, we developed O-SP conjugates of S. enterica serovar Paratyphi A designed to elicit IgG LPS antibodies in serum (35) .
The O-SP of S. enterica serovar Paratyphi A is composed of a trisaccharide backbone with a branch of D-paratose from the C-3 of ␣-D-mannose; C-3 of the adjacent ␣-L-rhamnose is partially O acetylated (8, 9, 23, 27) (Fig. 1) .
S. enterica serovar Paratyphi A O-SP required O-acetyl groups to elicit serum LPS antibody with bactericidal activity in mice (33) . O-SP was activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) at neutral pH and bound either directly or through an adipic acid hydrazide linker to the protein (33, 35, 38) . In mice, S. enterica serovar paratyphi A conjugates induced LPS antibody with group-specific bactericidal activity against serogroup A.
We describe a clinical evaluation of S. paratyphi A O-SP, bound to tetanus toxoid (TT) directly or through an adipic acid hydrazide spacer, in adults, teenagers, and 2-to 4-year-old children.
MATERIALS AND METHODS
Investigational vaccines. The O-SP was prepared as described previously and had a molar ratio of 0.71 O-acetyl groups per repeating unit of polysaccharide (33) . Pasteur-Mérieux Serum et Vaccins, Lyon, France, provided TT (lot GYA). Conjugates of the O-SP of S. enterica serovar Paratyphi A bound to TT through a linker, adipic acid dihydrazide (SPA-TT 1 ; lot 64811), or directly (SPA-TT 2 , lot 64812) have been described previously (13, 35) . SPA-TT 1 contained 30.2 g of protein per ml and 48.6 g of polysaccharide per ml, and SPA-TT 2 contained 40.7 g of protein per ml and 51.3 g of polysaccharide per ml; the dose for both conjugates was 0.5 ml. Both lots passed the Food and Drug Administration requirements for sterility, pyrogenicity, and general safety.
Study protocol. The investigation was approved by the Ministry of Health of Vietnam; the Institutional Review Board of the National Institute of Child Health and Human Development, National Institutes of Health (protocol OH96-CH-N023); the Office of Protection from Research Risks; and the Food and Drug Administration (BB IND 6530). Informed consent was obtained from adult volunteers and from parents or guardians of vaccinees younger than 18 years.
The site was Cao Lânh District, Dong Thap Province, of the Mekong Delta region of southern Vietnam. Twenty healthy adults were randomly assigned to receive one 0.5-ml injection of either SPA-TT 1 or SPA-TT 2 in the deltoid muscle. The vaccinees were examined at 30 min and at 6, 24, and 48 h following immunication. Reactions at the immunization sites were inspected, and the temperatures of the volunteers were measured; these findings were recorded. Side effects were defined as a fever of Ͼ38.5°C, erythema of Ͼ2.5 cm, or induration of Ͼ2 cm within 48 h of the injection. Sera were obtained before and at 6 and 26 weeks after vaccination and stored at Ϫ70°C. When it was confirmed that adults did not experience significant side effects, 108 teenagers between 13 and 17 years old were injected with one of these two conjugates according to the same protocol. The IgG LPS antibody titers in serum in the two groups were assayed and SPA-TT 2 , which elicited higher geometric mean (GM) IgG LPS antibody levels in serum, was chosen for evaluation in the 2-to 4-year-old children. A total of 110 children between 2 and 4 years old were injected with SPA-TT 2 . Half of the children were randomly assigned to receive a second dose 6 weeks later. Vaccinees were observed for adverse reactions at 30 min and 6, 24, and 48 h after each injection. Sera were collected before each injection and at 6, 10, and 26 weeks after the first injection.
LPS antibodies in serum. Sera were analyzed for IgG and IgM LPS antibodies by enzyme-linked immunosorbent assay (ELISA) (35) . Goat anti-human IgG or IgM conjugated to alkaline phosphatase (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) was the secondary antibody. The results are expressed in ELISA units (EU) as a percentage of a high-titer serum from an adult vaccinee. A response was defined as at least a fourfold rise in titer compared to the level at time zero. Bactericidal activity was assayed as described previously (34) . Antibodies to TT were measured by ELISA with a human tetanus immune globulin, titrated for its neutralizing activity, as a reference (14) . Results for TT antibodies are expressed in antitoxin units.
Statistical analyses. All antibody levels are expressed as GM. Levels below the sensitivity of the ELISA (0.1 EU) were assigned the value of one-half of that level (0.05 EU). Comparison of GMs was performed by either a paired or unpaired t test or the Wilcoxon test when appropriate.
RESULTS
Clinical observations. No significant side effects were reported for any of the three age groups.
LPS antibody levels in serum. (i) Prevaccination. All vaccinees had preexisting IgG and IgM antibodies in serum. The adults and 13-to 17-year-old teenagers had similar levels that were significantly higher than those in the 2-to 4-year-old children (1.46, 1.70, and 0.85 EU, respectively, for IgG [P Ͻ 0.05]; 17.5, 22.6, and 6.80, EU, respectively, for IgM [P ϭ 0.0001]).
(ii) Adults. At 6 weeks after injection, 75% of the adults responded with at least a fourfold rise in the IgG anti-LPS titer ( Table 1) . Recipients of SPA-TT 2 had higher IgG anti-LPS levels than did recipients of SPA-TT 1 (27.3 and 9.82 EU, respectively [not significant]) at 42 days following injection. These levels fell about threefold at 180 days but were still higher than the prevaccination levels (8. 28 . IgM anti-LPS levels at the 180-day interval declined to levels similar to those prior to the vaccination.
(iii) Teenagers. Conjugate-induced IgG anti-LPS levels in the 13-to 17-year-old volunteers were similar to but slightly lower than those in the adults (Table 1 ). At the 6-week interval, 85% responded with at least a fourfold rise in the IgG anti-LPS titer (P ϭ 0.0001). Recipients of SPA-TT 1 had a 7.6-fold rise to 12.8 EU, and recipients of SPA-TT 2 elicited a 10.2-fold rise to 17.4 EU (P Ͼ 0.01). At 180 days after vaccination, the IgG anti-LPS titers had declined about 50% compared to those at 42 days: the level elicited by SPA-TT 2 was only slightly higher than that elicited by the SPA-TT 1 (7.37 and 6.72 EU, respectively, P Ͼ 0.05). These levels were higher than the preimmune levels (6.72 versus 1.69, and 7.37 versus 1.70 EU [P ϭ 0.0001]).
As with IgG anti-LPS, the IgM responses in serum elicited by the two conjugates were similar to those observed in the adults. At the 42-day interval, the IgM anti-LPS titer had risen 1.4-fold (P ϭ 0.0001) in the SPA-TT 1 group and 1.5-fold (P ϭ 0.0001) in the SPA-TT 2 group. At 180 days, the IgM anti-LPS levels in the teenagers and adults were similar to each other and to the prevaccination levels.
Based on these results, only SPA-TT 2 was evaluated in 2-to 4-year-old children.
(iv) Children. About 90% of the children had at least a fourfold rise in their IgG anti-LPS titer at the 42-day interval IgM anti-LPS responses were slightly different from those of the teenagers and adults. The rises in IgM anti-LPS titers were slightly higher (ca. fourfold), although the levels at 42 days were similar to those in the teenagers and adults. As with IgG, there was no booster response to a second injection. At 180 days, IgM anti-LPS levels were higher in the children than in the teenagers and adults and were about twofold higher than the prevaccination levels (15.9 versus 6.65, and 17.6 versus 7.00 EU [P ϭ 0.0001]).
(v) Summary. GM IgG anti-LPS levels in serum in vaccinees of the three age groups are summarized in Table 3 . The levels of anti-LPS in the preimmune sera were similar for the adults and teenagers; both of these groups had higher levels than did the children. Both the levels and fold rises elicited by SPA-TT 2 were slightly but not significantly higher than those elicited by SPA-TT 1 . With the exception of SPA-TT 1 in the adults, there was a gradual decline in the IgG anti-LPS levels at 180 days that was age related.
Serum bactericidal levels. Representative sera (10) from the three age groups were assayed for their bactericidal titer (Table 4). Two pairs of sera from the children, prevaccination and after the first vaccination, were assayed, and their bactericidal titers were compared to the IgG and IgM anti-LPS titers by ELISA. All these sera had a bactericidal activity that required complement. The bactericidal activity was roughly related to the IgG anti-LPS titer. Adsorption of these sera with the LPS of S. enterica serovar Paratyphi A removed most of the bactericidal activity (data not shown).
Anti-TT levels in serum. All volunteers had preexisting IgG anti-TT: the children had the highest levels among the three age groups, probably due to their comparatively recent immunization with DTP. The levels at 180 days following injection were similar to those at 42 days in the adults and teenagers. In the children, the anti-TT levels at 180 days declined to about one-third the levels at 42 days but were higher than those in the adults and teenagers (3.62 and 4.10 versus 0.33 and 0.24 for teenagers and 0.48 and 0.56 for adults [P ϭ 0.0001]). As observed for LPS antibodies, SPA-TT 2 elicited slightly higher levels and fold rises of TT antibody for all three age groups than SPA-TT 1 did. At 180 days, the children receiving two injections had slightly higher levels of TT antibody than did those receiving only one injection (9.8 and 7.7, respectively [P Ͼ 0.05]).
DISCUSSION
Enteric fever is a systemic infection caused by S. enterica serovar Typhi and salmonellae of groups A to D (21, 32, 53) . We proposed that a critical level of IgG LPS antibody in serum could initiate complement-mediated lysis of these pathogens as they enter the intestine (50, 52, 61) . Vaccination with the surface polysaccharide of S. enterica serovar Typhi (Vi) prevents typhoid fever (65) . The immune moiety elicited by Vi is mainly serum IgG antibody (51) . The O-SP of S. enterica serovar Paratyphi A alone is not immunogenic (hapten) due to its comparatively low molecular weight (30, 35, 60) . The failure of whole-cell bacterial vaccines, such as TAB, to confer protection against group A and B salmonellae may be likened to the failure of parenterally injected inactivated gram-negative bacteria to induce high levels of IgG LPS antibodies (6, 18; T. A. Schwartzer, D. V. Alcid, V. Numsuwan, and D. J. Gocke, S. enterica serovar Paratyphi A is a pathogen of humans only, and we propose that conjugate-induced bactericidal antibodies will provide a correlate for protection (35, (50) (51) (52) 61) . Subcutaneous injection of mice with S. enterica serovar Paratyphi A conjugates using only 1/10 of a human dose in saline elicited bactericidal antibodies specific for group A but not group B Salmonella (35) . This is consistent with the immunodominant region of the group-specific antigen (factor 2), conferred by paratose, as predicted from the proposed structures of group A, B, and D O-SPs of salmonellae (8) (9) (10) 17) .
Earlier, we found that O-acetyl groups on the O-specific polysaccharide of S. enterica serovar Paratyphi A are essential for its immunogenicity and that conjugation with CDAP is useful for synthesis of S. enterica serovar Paratyphi A conjugates to preserve O-acetyl epitopes (35, 38) . Activation by CDAP occurs at neutral pH and does not reduce O-acetyls on the O-SP. CDAP-activated O-SP, bound directly to TT without a spacer (SPA-TT 2 ), elicited the highest level of TT antibodies (P Ͻ 0.005) as well as slightly higher level of anti-LPS.
SPA-TT 2 did not elicit a booster response in the 2-to 4-yearold group. This is in contrast to the booster response elicited in this age group by our pneumococcus type 6B-TT, Vi-rEPA, and Shigella flexneri 2a-rEPA conjugates (4, 54) . There is no explanation for these differing properties of polysaccharideprotein conjugates. We plan to evaluate the S. enterica serovar Paratyphi A O-SP conjugate in infants, an age group that shows booster responses to conjugate vaccines (51) .
The C-3 of rhamnose of the O-SP is partially O acetylated (27) . We found a molar ratio of 0.71 O-acetyl per repeat unit (35) . However, we detected two acetamido signals in the 13 C nuclear magnetic resonance spectrum. The O-SP of S. typhimurium (group B) is 2-O acetylated at abequose, conferring the specificity defined as factor 5 (8, 9). Carlin et al. reported that a murine monoclonal IgA antibody to factor 5 had low protective activity against S. enterica serovar Typhimurium (10) . It cannot be concluded that the O-acetyl does not have important biological activity for group B Salmonella because IgA may not protect against blood-borne infection. The failure of de-O-acetylated O-SP of S. enterica serovar Paratyphi A to induce bactericidal antibodies in mice might be due to the fact that paratose (factor 2 or group-specific antigen) is partially O acetylated. Since antibody-mediated immunity to nontyphoidal salmonellae is largely group specific and since the dideoxy sugars are essential for this specificity (8, 9, 17) , the location(s) and immunologic roles of O-acetyls in O-SP of groups A, B, and D should be investigated further. O-acetyls are essential for expression of the protective action of other polysaccharides (5) .
In summary, S. enterica serovar Paratyphi A O-specific polysaccharide-TT conjugates were safe and elicited IgG antibodies with bactericidal activity in the serum of adults, teenagers, and 2-to 4-year-old children. There is sufficient information about Vi (65), with S. enterica serovar Typhimurium O-SP conjugates in mice (10, 16, 64) and clinical studies with Shigella O-SP conjugates (15) , to evaluate our S. enterica serovar Paratyphi A conjugates for efficacy. If effective, O-SP conjugates against group B, C, and D Salmonella should also protect against nontyphoidal enteric fever. 
